Biostem Technologies 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OID
BioStem Technologies' Q3 2026 report reveals a significant revenue decrease and net loss, impacted by CMS reimbursement changes, though a recent acquisition shows promise.
OID
BioStem Technologies' Q2 2026 Form 10-Q reveals a significant revenue decrease and increased operating costs, leading to a substantial net loss, though offset by a strategic acquisition and ongoing financing efforts.